Cargando…
The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
PURPOSE: BMI1, which is a major component of the polycomb group complex 1, is an essential epigenetic repressor of multiple regulatory genes and has been identified as a cancer stem cell (CSC) marker in several cancers. However, its role in breast cancer (BC) remains to be defined. In this study, we...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320923/ https://www.ncbi.nlm.nih.gov/pubmed/32524353 http://dx.doi.org/10.1007/s10549-020-05719-x |
_version_ | 1783551345988468736 |
---|---|
author | Althobiti, Maryam Muftah, Abir A. Aleskandarany, Mohammed A. Joseph, Chitra Toss, Michael S. Green, Andrew Rakha, Emad |
author_facet | Althobiti, Maryam Muftah, Abir A. Aleskandarany, Mohammed A. Joseph, Chitra Toss, Michael S. Green, Andrew Rakha, Emad |
author_sort | Althobiti, Maryam |
collection | PubMed |
description | PURPOSE: BMI1, which is a major component of the polycomb group complex 1, is an essential epigenetic repressor of multiple regulatory genes and has been identified as a cancer stem cell (CSC) marker in several cancers. However, its role in breast cancer (BC) remains to be defined. In this study, we have evaluated the prognostic significance of BMI1 among the different molecular subtypes and assessed its association with other breast CSC markers (BCSC). MATERIAL AND METHOD: BMI1 copy number and mRNA was assessed in large and well-characterised cohorts of early-stage BC patients [METABRIC (n = 1980) and the Bc-GenExMiner (n = 9616) databases]. BMI1 protein expression was assessed using tissue microarray and immunohistochemistry in a cohort of 870 invasive BC patients with long-term outcome data and the expression of a panel of BCSC markers was monitored. RESULT: BMI1 expression, prognostic significance and its association with BCSC markers were differed between molecular classes. In the luminal oestrogen receptor-positive (ER+) BC, BMI1 showed significantly higher expression compared to ER− tumours. BMI1 showed positive correlation with favourable prognostic features and it was negatively associated with the expression of key BCSC markers (ALDH1A1, CD24, CD44, CD133, SOX10 and SOX9). High expression of BMI1 was associated with longer breast cancer-specific survival (BCSS) independent of other prognostic variables. In the basal triple negative BC subtype, BMI1 expression showed positive association with CD133 and SOX10 and it was significantly associated with shorter BCSS. CONCLUSION: High BMI1 expression is associated with clinicopathological variables and outcome in BC. However, this association is dependent on the molecular subtypes. Further functional assessment to detect its underlying mechanistic roles in BC subtypes is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-020-05719-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7320923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-73209232020-07-01 The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes Althobiti, Maryam Muftah, Abir A. Aleskandarany, Mohammed A. Joseph, Chitra Toss, Michael S. Green, Andrew Rakha, Emad Breast Cancer Res Treat Preclinical Study PURPOSE: BMI1, which is a major component of the polycomb group complex 1, is an essential epigenetic repressor of multiple regulatory genes and has been identified as a cancer stem cell (CSC) marker in several cancers. However, its role in breast cancer (BC) remains to be defined. In this study, we have evaluated the prognostic significance of BMI1 among the different molecular subtypes and assessed its association with other breast CSC markers (BCSC). MATERIAL AND METHOD: BMI1 copy number and mRNA was assessed in large and well-characterised cohorts of early-stage BC patients [METABRIC (n = 1980) and the Bc-GenExMiner (n = 9616) databases]. BMI1 protein expression was assessed using tissue microarray and immunohistochemistry in a cohort of 870 invasive BC patients with long-term outcome data and the expression of a panel of BCSC markers was monitored. RESULT: BMI1 expression, prognostic significance and its association with BCSC markers were differed between molecular classes. In the luminal oestrogen receptor-positive (ER+) BC, BMI1 showed significantly higher expression compared to ER− tumours. BMI1 showed positive correlation with favourable prognostic features and it was negatively associated with the expression of key BCSC markers (ALDH1A1, CD24, CD44, CD133, SOX10 and SOX9). High expression of BMI1 was associated with longer breast cancer-specific survival (BCSS) independent of other prognostic variables. In the basal triple negative BC subtype, BMI1 expression showed positive association with CD133 and SOX10 and it was significantly associated with shorter BCSS. CONCLUSION: High BMI1 expression is associated with clinicopathological variables and outcome in BC. However, this association is dependent on the molecular subtypes. Further functional assessment to detect its underlying mechanistic roles in BC subtypes is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-020-05719-x) contains supplementary material, which is available to authorized users. Springer US 2020-06-10 2020 /pmc/articles/PMC7320923/ /pubmed/32524353 http://dx.doi.org/10.1007/s10549-020-05719-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Preclinical Study Althobiti, Maryam Muftah, Abir A. Aleskandarany, Mohammed A. Joseph, Chitra Toss, Michael S. Green, Andrew Rakha, Emad The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes |
title | The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes |
title_full | The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes |
title_fullStr | The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes |
title_full_unstemmed | The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes |
title_short | The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes |
title_sort | prognostic significance of bmi1 expression in invasive breast cancer is dependent on its molecular subtypes |
topic | Preclinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320923/ https://www.ncbi.nlm.nih.gov/pubmed/32524353 http://dx.doi.org/10.1007/s10549-020-05719-x |
work_keys_str_mv | AT althobitimaryam theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT muftahabira theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT aleskandaranymohammeda theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT josephchitra theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT tossmichaels theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT greenandrew theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT rakhaemad theprognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT althobitimaryam prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT muftahabira prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT aleskandaranymohammeda prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT josephchitra prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT tossmichaels prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT greenandrew prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes AT rakhaemad prognosticsignificanceofbmi1expressionininvasivebreastcancerisdependentonitsmolecularsubtypes |